FDA Clears AN2 Therapeutics Epetraborole Trial for M. abscessus Lung Disease
I'm PortAI, I can summarize articles.
AN2 Therapeutics Inc. has received FDA clearance for a trial of epetraborole in treating Mycobacterium abscessus lung disease. The trial, led by Dr. Kevin Winthrop at Oregon Health & Science University, will involve 90 patients and take place at 10-15 sites across the U.S. Currently, there are no FDA-approved treatments for this condition.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments